News | May 28, 2021
Bharat Biotech signs MoU with GCVC for COVID Vaccine
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence
Focus on preventive, tech-driven healthcare and digital ecosystem reforms under AB PM-JAY and ABDM
Dr Shivkumar Kalyanaraman emphasizes need for quality research, partnerships, and measurable outcomes
Bidding window open till May 15; study to map costs and bottlenecks across pharma supply chains
Among his notable contributions is the development of the NAGI Stent, a widely adopted device for the drainage of pancreatic pseudocysts
Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines
The investment case for health technology in India is frequently overstated in one direction and understated in another
Subscribe To Our Newsletter & Stay Updated
